Investigation of the efficacy of siRNA-mediated KRAS gene silencing in pancreatic cancer therapy
PeerJ · 2024
DOI: 10.7717/peerj.18214 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2024. Verfasst von Büşra Küçükekmekci und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Sciences, Department of Biology, Kırıkkale University, Kırıkkale, Yahşihan, Turkey. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, RNA, Small Interfering, Proto-Oncogene Proteins p21(ras), Metal Nanoparticles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kırıkkale University Scientific Research Projects.
Abstract (Originalsprache)
Aim
Pancreatic carcinoma is an aggressive cancer that progresses without many symptoms. The difficulty of early diagnosis and an inadequate response to traditional treatments also cause the survival rate of pancreatic cancer to be low. Current research is focusing on methods of diagnosis and treatment, such as gene therapy, to increase survival rates. Small interfering ribonucleic acid (siRNA) has emerged as a promising advanced therapeutic strategy for cancer treatment. This study sought to silence the KRAS gene in the human pancreatic carcinoma cell line using a complex of small interfering ribonucleic acid (siRNA) and gold nanoparticles (AuNP).
Methods
In this study, 25 nM siRNA and gold nanoparticles at 0.5 mg/ml, 0.25 mg/ml, and 0.125 mg/ml concentrations were used to silence the KRAS gene in the CAPAN-1 cell line. Real-time PCR analysis, agarose gel electrophoresis, and double staining were carried out, and xCelligence real-time cell analysis (RTCA) was used to measure proliferation.
Results
The PCR analysis revealed crossing point (CP) values of actin beta (ACTB) ranging from 33.04 to 35.98, which was in the expected range for all samples. The interaction between the gold nanoparticle/siRNA complex in the double staining analysis revealed that the most effective concentration of gold nanoparticle was 0.125 mg/ml. The WST-1 technique showed that siRNA/AuPEI cells in application groups had a viability rate of over 90%, indicating no toxicity or side effects. The xCELLigence RTCA® showed that at hour 72, there was a significant difference in proliferation in the 0.5 mg/mL PEI/AuNP-siRNA, 0.25 mg/mL PEI/AuNP-siRNA, and 0.125 mg/mL PEI/AuNP-siRNA application groups compared to the control and siRNA groups ( p < 0.05). By hour 96, all three groups were statistically different from the control and siRNA groups in terms of proliferation ( p < 0.05).
Conclusions
The results of this analysis suggest that the AuPEI/siRNA complex can be effectively used to silence the target gene, but more studies are needed to verify these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Sciences, Department of Biology, Kırıkkale University, Kırıkkale, Yahşihan, Turkey.
- Vocational High School of Health Care Services, Department of Medical Services and Techniques, Kırıkkale University, Kırıkkale, Yahşihan, Turkey.
Förderung
- Kırıkkale University Scientific Research Projects
Zitieren
APA
Küçükekmekci, B., & Budak Yıldıran, F. A. (2024). Investigation of the efficacy of siRNA-mediated KRAS gene silencing in pancreatic cancer therapy. PeerJ. https://doi.org/10.7717/peerj.18214
Vancouver
Küçükekmekci B, Budak Yıldıran FA. Investigation of the efficacy of siRNA-mediated KRAS gene silencing in pancreatic cancer therapy. PeerJ. 2024. doi:10.7717/peerj.18214
BibTeX
@article{Kkekmekci2024,
author = {Küçükekmekci, Büşra and Budak Yıldıran, Fatma Azize},
title = {Investigation of the efficacy of siRNA-mediated KRAS gene silencing in pancreatic cancer therapy},
journal = {PeerJ},
year = {2024},
doi = {10.7717/peerj.18214}
}
EUVIMED